MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-14-2024
Motus GI Holdings Interest Expense 2011-2025 | MOTS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Motus GI Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 211 | 128 | 453 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 453 K | 128 | 151 K |
Quarterly Interest Expense Motus GI Holdings
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85 K | - | 281 K | 285 K | 308 K | - | 338 K | 356 K | 327 K | - | 193 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 356 K | 85 K | 272 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 20.7 | -2.24 % | $ 223 M |  China |
 |
Co-Diagnostics
CODX
|
106 K | $ 0.23 | -3.87 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 39.2 | -0.51 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 230.43 | 0.05 % | $ 168 B | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 10.56 | 5.18 % | $ 300 M |  Israel |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.51 | -0.95 % | $ 1.92 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.85 | 0.28 % | $ 18.9 B | USA |
 |
DexCom
DXCM
|
20.3 M | $ 67.71 | 0.21 % | $ 26.1 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 26.63 | -0.34 % | $ 805 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 19.04 | -2.26 % | $ 1.02 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 101.24 | -0.99 % | $ 3.99 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.19 | -0.47 % | $ 102 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 226.71 | -0.09 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 101.95 | -1.01 % | $ 12.5 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 7.23 | 1.4 % | $ 1.57 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 6.35 | -2.01 % | $ 575 M | USA |
 |
National Research Corporation
NRC
|
862 K | $ 18.92 | 1.39 % | $ 464 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.81 | -5.39 % | $ 2.58 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 27.26 | 0.55 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
24 K | $ 8.05 | -1.11 % | $ 477 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 133.97 | -0.73 % | $ 21.3 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 203.01 | -0.32 % | $ 10.4 B | USA |
 |
RadNet
RDNT
|
24.9 M | $ 73.05 | -0.14 % | $ 5.34 B | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 47.74 | 0.19 % | $ 1.92 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 175.29 | -0.37 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 6.73 | -1.32 % | $ 873 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 252.89 | -0.39 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 182.85 | 0.01 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 683.4 | -0.74 % | $ 56.4 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 67.01 | 0.45 % | $ 4.64 B | USA |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 413.2 | -0.49 % | $ 30 B |  Schweiz |